Due to a shortage of radiologists and other imaging specialists, AI-enabled technologies are of significant interest—and hold particular promise—in medical imaging. In this article, Penny Pinnock of Siemens Financial Services (SFS), discusses the routes to investment available for healthcare organizations looking to acquire efficiency boosting technology while protecting their financial health.
The Rubitection skin assessment management tool for chronic wounds and Kofimi Technology’s pediatric pulse oximeter device received a combined $50,000 in grant funding as part of the ADPI-led pitch competition.
How innovators in the femtech space can protect their inventions and defend market share.
The doctrine of assignor estoppel is intended to prevent an inventor who has sold or “assigned” a patent from then challenging the patent’s validity. Mauricio Uribe, a patent lawyer with Knobbe Martens, discusses what medical device inventors and acquiring companies should do to ensure they comply with the Supreme Court and Federal Circuit’s clarification of assignor estoppel.
Mahofski will be responsible for identifying and pursuing acquisition opportunities that complement RQM+’s core regulatory services and provide a comprehensive range of fully integrated outsourced solutions to help get MedTech products to market faster and ensure ongoing regulatory compliance.
The MDDT program was developed in collaboration with the National Institutes of Health’s (NIH’s) National Institute of Drug Abuse (NIDA), National Institute of Dental Craniofacial Research (NIDCR) and National Cancer Institute (NCI) as a way for the FDA to qualify tools that medical device sponsors can use in the development and evaluation of medical devices.
Leslie Storms, U.S. president of Ethicon, Martha Shadan, chairwoman of Brilliant Springs Therapeutics, and Kristine Ilaria, vice president of Corporate Development at Smith+Nephew, share lessons learned from their panel “Making Acquisition Strategy Succeed: Perspectives from Both Sides of The Deal.”
The order outlines a “whole-of-government approach” to advance biotechnology and biomanufacturing towards innovative solutions in health, climate change, energy, food security, agriculture, supply chain resilience and national and economic security.
“M.I.Tech is an innovator in nonvascular stent development, with product offerings that complement our existing stent portfolio.”
Although many elective procedures were canceled during the course of the pandemic, the market has not been negatively affected.
